Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era
Abstract
Chikungunya fever is becoming a major healthcare threat in more than 110 countries and may impact a total population of 2.8 billion, particularly those in East and Central Africa, South America, and Southeast Asia.1,2 VLA1553 (live-attenuated, single-dose, trade name IXCHIQ) and PXVX0317 (purified virus-like particles, trade name Vimkunya) are the two approved vaccines for Chikungunya virus (CHIKV).3-6 Their seroconversion rates were more than 95%, while their approval, accessibility, and indications differ across countries/regions.5,6 They thus will shift the paradigm
Fields of Study & Subjects
Mosquito-borne diseases and control
Biological Research and Disease Studies
Herbal Medicine Research Studies
Publication details
- Journal / source
- Future Integrative Medicine
- Publisher
- Xia & He Publishing
- Volume
- 000
- Issue
- 000
- Pages
- 000–000
- Publication date
- 11 June 2026
- Language
- EN